Tolvaptan Q&A Live with Professor Daniel Gale - 4 July 2022

Tolvaptan is a treatment for autosomal dominant polycystic kidney disease (ADPKD) adults that can help slow the progression of ADPKD.

Professor Daniel Gale, Honorary Consultant Nephrologist at Royal Free Hospital, London, chaired a Q&A session with patients, family members and carers diagnosed with ADPKD.

Topics included:

ADPKD progression
Eligibility for tolvaptan
Benefits and risks
Side effects

Medical Disclaimer:
This is for information only.​
It is not a substitute for professional medical advice or medical examination​.
Always consult your doctor, pharmacist or other medical professional if you have any concerns about your care or before taking any treatment​.
We do not promote or recommend any treatment or brand​​.

​

​